Clinical Trial Search

Primary: Time to Improvement of Influenza Symptoms — 73.2; 102.3; 81.0 hours — p=<0.0001

Primary: Mean Hb Change Level During the Last Four Weeks of Treatment — 0.4; 0.74 g/dL

Primary: The Number of On-treatment Pregnancies (With + 7-day Window) Per 100 Woman-years of Exposure (Pearl Index) in Subjects Aged 16 to 35 Years, Inclusive, at the Time of…

Primary: Number of Participants With Occurrence of Any Treatment Emergent Adverse Event (TEAE) — 277; 27; 275; 267 Participants

Primary: Mean Nasal Symptom Score — 3.66; 4.69 score — p=<0.001

Primary: Change From Baseline in HbA1c at the End of Treatment Period I — -0.71; 0.01 Percent HbA1c — p=<0.0001

Primary: Occurrence, Seriousness, Severity, and Causality Assessment of Treatment Emergent Adverse Events (TEAE) — 7; 14; 3; 2 participants

Primary: Percentage of Participants With Human Immunodeficiency Virus-1 Ribonucleic Acid (HIV-1 RNA) < 50 Copies/mL at Week 12 as Defined by Pure Virologic Response (PVR)…

Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) — 280 Participants

Primary: Anti-glycoprotein (gE) Specific Antibody (Ab) Concentrations — 9122.9 mIU/mL

Primary: Change From Baseline to End of Study in Hemoglobin A1c (HbA1c) — -0.227; -0.227 percentage of hemoglobin A1c (HbA1c)

Primary: Number of Seroprotected Subjects With Anti-diphtheria (Anti-D) and Anti-tetanus (Anti-T) Antibody Concentrations Above or Equal to Cut-off Value. — 478; 486; 486; 495…

Primary: Change From Baseline in Best Corrected Visual Acuity (BCVA) (Letters Read) at Week 48 - Study Eye — 6.9; 7.6 letters — p=<0.0001

Primary: Change From Baseline in Best Corrected Visual Acuity (BCVA) (Letters Read) at Week 48 - Study Eye — 5.9; 6.4; 7.0 letters — p=0.0003

Primary: Percentage of Participants Achieving ASAS 20 (SpondyloArthritis International Society Criteria) Response at Week 16 — 41.1; 61.1; 28.4 percentage of participants…